Bexicaserin

Copenhagen, Denmark, September 15, 2026 H. Lundbeck A/S has announced that the last patient has been randomized in DEEp...

Jerusalem, Israel, August 31, 2026 Alpha Tau Medical Ltd. has completed patient enrollment in its multicenter IMPACT (Intratumoral Pancreatic...

The Woodlands, Texas, USA, September 1, 2026 Autonomix Medical, Inc. announced that two scientific abstracts featuring its transvascular nerve-targeting...

Valby, Denmark, September 3, 2026 H. Lundbeck A/S will present new mechanistic and clinical research on bexicaserin (LP352) at...

VALBY, Denmark, July 20, 2026 H. Lundbeck A/S has reached a major clinical development milestone with the last patient...

CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics has unveiled encouraging late-breaking Phase IIa clinical results for its investigational immunotherapy...